Warning: Declaration of Suffusion_MM_Walker::start_el($output, $item, $depth, $args) should be compatible with Walker_Nav_Menu::start_el(&$output, $item, $depth = 0, $args = Array, $id = 0) in /home/hygiol5/public_html/wp-content/themes/suffusion/library/suffusion-walkers.php on line 39
May 062013
 

The Hygiology Post ®  is presenting information about a company that seems to have much potential to help many people. Both 2012 and 2013 appear to be pivotal years in determining how helpful the patented technologies may actually be for people. Senesco Technologies has continued to update information on its web site (https://www.senesco.com/; obtained on 05-06-13). As a matter of disclosure : The author continues to be a current shareholder in the company.  

The following article titled “Senesco Announces Start of Cohort 3 in Phase 1b/2a Study in Multiple Myeloma and Non-Hodgkins B-Cell LymphomaData Review Committee Approves Dose Escalation” (https://finance.yahoo.com/news/senesco-announces-start-cohort-3-123000503.html; retrived on 5-6-13) was apparently released this morning by “Business Wire” and began in the following way:
 
 “…Senesco Technologies, Inc. (“Senesco” or the “Company”) (OTC QB: SNTI) reported today that the Data Review Committee (DRC) for its SNS01-T trial in multiple myeloma and non-Hodgkins B-cell lymphoma approved initiating cohort 3 and escalating the SNS01-T dose level four-fold to 0.2 mg/Kg. The DRC’s review of the results of cohort 2 concluded that SNS01-T was safe and well tolerated at a dose of 0.05 mg/Kg. No drug-related serious adverse events or dose limiting toxicities were observed in either of the first two cohorts.’Senesco has seen disease stabilization and no drug-related safety issues at the lower dose levels in the SNS01-T study, stated Brian G.M. Durie, M.D., Director of Research and Myeloma Programs at Cedars-Sinai Comprehensive Cancer Center in Los Angeles and independent member of Senesco’s DRC. ‘However, now that patients will be receiving higher doses, Senesco has the opportunity to ascertain whether SNS01-T can show significant efficacy in patients as well.’SNS01-T has demonstrated statistically significant inhibition of tumor growth and survival in mouse models of multiple myeloma, diffuse large B-cell lymphoma and mantle cell lymphoma at the 0.375 mg/Kg and 0.2 mg/Kg, the dose level that will be administered in cohort 3.’We are very pleased that SNS01-T appears to be well tolerated in cohorts 1 and 2,’ stated Harlan Waksal, M.D., Chairman of Senesco. ‘In cohort 3 patients will now be receiving dose levels of SNS01-T that are in the same range where we started to observe efficacy in preclinical cancer models.’

The study is an open-label, multiple-dose, dose-escalation study to evaluate the safety and tolerability of SNS01-T when administered by intravenous infusion to approximately 15 relapsed or refractory multiple myeloma, mantle cell (MCL) or diffuse large B-cell lymphoma (DLBCL) patients. While the primary objective is to evaluate safety and tolerability, the effect of SNS01-T on tumor response and time to relapse or progression will be assessed using multiple well-established metrics including measurement of monoclonal protein in multiple myeloma and CT imaging in MCL and DLBCL .

In the study, patients are dosed twice-weekly by intravenous infusion for 6 weeks followed by an observation period. The first group of patients received 0.0125 mg/kg per dose. The second group received 0.05 mg/kg and the planned dose levels for the third and fourth groups are 0.2 and 0.375 mg/kg, respectively. The top dose planned is 30 fold higher than the starting dose in cohort 1.”

 

The Hygiology Post ® welcomes feedback from readers as to whether the articles (individually and/or collectively) help fulfill its vision and mission.

 

Louis DeCola, Jr.                                    © 2013 The Hygiology Post ®